In recent times there is a shortfall of care about ectopic pregnancy among everyone, inciting conceded finding and potentially non -violent results. Ectopic pregnancy is a very dangerous medical disorder. This occurs when a fertilised egg implants outside of the uterus, generally in the fallopian tube. Making up 5%–10% of all pregnancy-related deaths, ectopic pregnancies are the leading cause of maternal death in the first trimester. Methotrexate is a folic acid inhibitor. It interferes with DNA synthesis and cell multiplication by inhibiting the spontaneous synthesis of purines and pyrimidines. Methotrexate will be used in the middle of six and eight weeks of pregnancy. The likelihood of a future pregnancy succeeding after using methotrexate is generally positive, according to studies. However, a few things could have an impact on these odds. As per to research, ectopic pregnancies are more common among women of reproductive age, usually between the ages of 20 and 35. Given that they are more likely to be sexually active and trying to get pregnant, women in this age range are at their most fertile. Additionally, the prevalence of sexually transmitted diseases (STIs) is higher in this age group, which can mark up the chance of an ectopic pregnancy. Factors affecting ectopic pregnancy risk include previous pelvic surgeries, infections, in vitro fertilization [IVF], endometriosis, smoking, assisted reproductive technologies, and tubal sterilization or previous pregnancies. This review of the literature attempts to shed insight on how methotrexate is currently used to treat ectopic pregnancies
近来，每个人都对宫外孕缺乏关注，从而导致了误诊和潜在的非暴力结果。宫外孕是一种非常危险的疾病。当受精卵着床于子宫以外的地方，通常是输卵管时，就会发生宫外孕。宫外孕占所有妊娠相关死亡的 5%-10%，是妊娠头三个月孕产妇死亡的主要原因。甲氨蝶呤是一种叶酸抑制剂。它通过抑制嘌呤和嘧啶的自发合成来干扰 DNA 合成和细胞繁殖。甲氨蝶呤将在怀孕六周和八周中期使用。根据研究，使用甲氨蝶呤后未来成功怀孕的可能性一般是积极的。不过，有几种情况可能会对这种可能性产生影响。根据研究，宫外孕在育龄妇女中更为常见，通常在 20 至 35 岁之间。鉴于她们更有可能性生活活跃并试图怀孕，这个年龄段的女性正处于生育能力最强的时期。此外，这个年龄段的女性性传播疾病（STI）发病率较高，这也会增加宫外孕的几率。影响宫外孕风险的因素包括既往盆腔手术、感染、体外受精（IVF）、子宫内膜异位症、吸烟、辅助生殖技术、输卵管绝育或既往妊娠。本文献综述试图深入探讨目前如何使用甲氨蝶呤治疗异位妊娠
{"title":"Virtue of methotrexate in ectopic pregnancy","authors":"Salma Shaik, Lakshmi Manasa Venkata Sai, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L","doi":"10.26452/fjphs.v4i1.563","DOIUrl":"https://doi.org/10.26452/fjphs.v4i1.563","url":null,"abstract":"In recent times there is a shortfall of care about ectopic pregnancy among everyone, inciting conceded finding and potentially non -violent results. Ectopic pregnancy is a very dangerous medical disorder. This occurs when a fertilised egg implants outside of the uterus, generally in the fallopian tube. Making up 5%–10% of all pregnancy-related deaths, ectopic pregnancies are the leading cause of maternal death in the first trimester. Methotrexate is a folic acid inhibitor. It interferes with DNA synthesis and cell multiplication by inhibiting the spontaneous synthesis of purines and pyrimidines. Methotrexate will be used in the middle of six and eight weeks of pregnancy. The likelihood of a future pregnancy succeeding after using methotrexate is generally positive, according to studies. However, a few things could have an impact on these odds. As per to research, ectopic pregnancies are more common among women of reproductive age, usually between the ages of 20 and 35. Given that they are more likely to be sexually active and trying to get pregnant, women in this age range are at their most fertile. Additionally, the prevalence of sexually transmitted diseases (STIs) is higher in this age group, which can mark up the chance of an ectopic pregnancy. Factors affecting ectopic pregnancy risk include previous pelvic surgeries, infections, in vitro fertilization [IVF], endometriosis, smoking, assisted reproductive technologies, and tubal sterilization or previous pregnancies. This review of the literature attempts to shed insight on how methotrexate is currently used to treat ectopic pregnancies","PeriodicalId":503124,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"402 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140490467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Degenerative joint disease, or osteoarthritis (OA), is a prevalent chronic synovial joint condition characterized by non-inflammatory degeneration, leading to pain and restricted joint movement. OA patients navigate a spectrum of therapeutic options, from social media advice to prescriptions from primary care physicians. This article critically assesses evidence-based treatments for generalized or monoarticular OA, advocating multidisciplinary and multimodal therapy. Evaluation covers patient education, pharmaceuticals, complementary and alternative medicine, surgery, manual techniques, acupuncture, bracing, assistive devices, physical therapy, modalities, and interventional procedures (corticosteroid injection, viscosupplementation, pulsed radiofrequency). Optimal benefits emerge from early diagnosis and prevention combined with multidisciplinary and multimodal treatments. The review highlights the synergy of complementary therapies. Healthcare professionals should be well-versed in diverse OA management resources, emphasizing tailored treatment plans aligned with individual needs and encouraging healthier lifestyle choices for optimal patient outcomes.Top of Form
退行性关节病或骨关节炎（OA）是一种普遍存在的慢性滑膜关节疾病，其特点是非炎症性退化，导致疼痛和关节活动受限。从社交媒体上的建议到初级保健医生开出的处方，OA 患者可选择的治疗方法多种多样。本文对全身性或单关节 OA 的循证疗法进行了严格评估，提倡多学科和多模式疗法。评估内容包括患者教育、药物、补充和替代医学、手术、手法、针灸、支具、辅助设备、理疗、模式和介入治疗（皮质类固醇注射、粘液补充、脉冲射频）。早期诊断和预防结合多学科和多模式治疗可带来最佳疗效。综述强调了辅助疗法的协同作用。医疗保健专业人员应精通各种 OA 管理资源，强调符合个人需求的定制治疗计划，并鼓励选择更健康的生活方式，以获得最佳的患者疗效。
{"title":"A review on osteoarthritis","authors":"Rabbani Shaik, Surya Sritaja Podila, Ijaz Sheik","doi":"10.26452/fjphs.v3i4.526","DOIUrl":"https://doi.org/10.26452/fjphs.v3i4.526","url":null,"abstract":"Degenerative joint disease, or osteoarthritis (OA), is a prevalent chronic synovial joint condition characterized by non-inflammatory degeneration, leading to pain and restricted joint movement. OA patients navigate a spectrum of therapeutic options, from social media advice to prescriptions from primary care physicians. This article critically assesses evidence-based treatments for generalized or monoarticular OA, advocating multidisciplinary and multimodal therapy. Evaluation covers patient education, pharmaceuticals, complementary and alternative medicine, surgery, manual techniques, acupuncture, bracing, assistive devices, physical therapy, modalities, and interventional procedures (corticosteroid injection, viscosupplementation, pulsed radiofrequency). Optimal benefits emerge from early diagnosis and prevention combined with multidisciplinary and multimodal treatments. The review highlights the synergy of complementary therapies. Healthcare professionals should be well-versed in diverse OA management resources, emphasizing tailored treatment plans aligned with individual needs and encouraging healthier lifestyle choices for optimal patient outcomes.Top of Form","PeriodicalId":503124,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139210872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gautham Chakra R, Chandana Sai Y, Jyoshna V, Likhitha K, Tejeswini N, Iswarya N, Naga Lakshmi N
The study aims to assess the current prescribing patterns for drugs managing Coronary Heart Disease (CHD) at the designated site to promote rational drug use in a specialized population. Conducted in the Medicine ward over six months, this observational retrospective study focused on patients consulting cardiologists for cardiac issues. Among lipid-lowering agents, rosuvastatin was the most prescribed (52.84%), followed by atorvastatin (43.15%). Anti-hypertensive agents were widely used, with beta-blockers, ACE inhibitors, and diuretics being popular choices. Adrenergic receptor blockers were common for hypertension, with metoprolol (55.7%) and bisoprolol (10.8%) frequently prescribed. ACE inhibitors, particularly Enalapril (65.6%), dominated prescriptions. Diuretics, including eplerenone (37.2%) and furosemide (33.3%), ranked third. The majority of patients were male, potentially linked to smoking and alcohol habits. Analysis revealed the prevalence of statins and anti-atherogenic agents in cardiovascular prescriptions. Beta-blockers, ACE inhibitors, and diuretics were prominent in managing hypertension.Top of Form
{"title":"The prescription pattern for coronary artery disease in tertiary care hospitals","authors":"Gautham Chakra R, Chandana Sai Y, Jyoshna V, Likhitha K, Tejeswini N, Iswarya N, Naga Lakshmi N","doi":"10.26452/fjphs.v3i4.525","DOIUrl":"https://doi.org/10.26452/fjphs.v3i4.525","url":null,"abstract":"The study aims to assess the current prescribing patterns for drugs managing Coronary Heart Disease (CHD) at the designated site to promote rational drug use in a specialized population. Conducted in the Medicine ward over six months, this observational retrospective study focused on patients consulting cardiologists for cardiac issues. Among lipid-lowering agents, rosuvastatin was the most prescribed (52.84%), followed by atorvastatin (43.15%). Anti-hypertensive agents were widely used, with beta-blockers, ACE inhibitors, and diuretics being popular choices. Adrenergic receptor blockers were common for hypertension, with metoprolol (55.7%) and bisoprolol (10.8%) frequently prescribed. ACE inhibitors, particularly Enalapril (65.6%), dominated prescriptions. Diuretics, including eplerenone (37.2%) and furosemide (33.3%), ranked third. The majority of patients were male, potentially linked to smoking and alcohol habits. Analysis revealed the prevalence of statins and anti-atherogenic agents in cardiovascular prescriptions. Beta-blockers, ACE inhibitors, and diuretics were prominent in managing hypertension.Top of Form","PeriodicalId":503124,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139238635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The development of nanoscience and nanotechnology in practically every field of science has simplified modern life. Since the arrangement of atoms in structures, electronics and systems produce their distinctive properties and functionalities on the scale of 1-100 nm. Beginning in the early 2000s, there was a rise in public discussion and understanding of the field which prompted the first commercial applications of nanotechnology. Nanotechnologies have a positive impact on almost all fields of study including physics, materials science, chemistry, biology, computer science and engineering. Notably, nanotechnologies have recently been employed with hopeful results to enhance human health, particularly in the field of cancer therapy. Understanding the nature of nanotechnology requires an understanding of the history of scientific discoveries that led to our current understanding of the field.
{"title":"Background, Trends, Applications and Therapeutic Approaches of Nanoparticles: A Review","authors":"Saravanakumar Kasimedu, Hemalatha Palavuri, Swathi Puchakayala, Dhanalakshmi Rayavarapu, Akash Govindan, Harshitha Debbati, Niranjan Babu Mudduluru","doi":"10.26452/fjphs.v3i4.523","DOIUrl":"https://doi.org/10.26452/fjphs.v3i4.523","url":null,"abstract":"The development of nanoscience and nanotechnology in practically every field of science has simplified modern life. Since the arrangement of atoms in structures, electronics and systems produce their distinctive properties and functionalities on the scale of 1-100 nm. Beginning in the early 2000s, there was a rise in public discussion and understanding of the field which prompted the first commercial applications of nanotechnology. Nanotechnologies have a positive impact on almost all fields of study including physics, materials science, chemistry, biology, computer science and engineering. Notably, nanotechnologies have recently been employed with hopeful results to enhance human health, particularly in the field of cancer therapy. Understanding the nature of nanotechnology requires an understanding of the history of scientific discoveries that led to our current understanding of the field.","PeriodicalId":503124,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139260014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Spinal muscular atrophy (SMA) is a form of muscle disease induced by SMN1 gene mutations. It can cause motor neurons and muscle strength to weaken. The intensity of the disease’s progression varies depending on the stage of development. Over the past ten years, new ways to help people with SMA have been found. These include the use of gene therapy and the modification of the SMN2 and SMN1 genes. First drugs approved for this condition were able to significantly alter the course of the disease. However, the evidence that is now available for these novel therapies is frequently constrained to a small range of individuals in terms of age and illness stage. To better understand the impact of treatment on people with all SMA subtypes and to build a platform for clinical decision-making in SMA, it will be necessary to gather real-world data with standardized outcome markers.
脊髓性肌萎缩症（SMA）是一种由 SMN1 基因突变诱发的肌肉疾病。它会导致运动神经元和肌肉力量减弱。该病的发展程度因发展阶段而异。过去十年间，人们发现了帮助 SMA 患者的新方法。其中包括使用基因疗法以及修改 SMN2 和 SMN1 基因。首批获批的药物能够显著改变疾病的进程。然而，就年龄和疾病阶段而言，这些新型疗法的现有证据往往局限于小范围的个体。为了更好地了解治疗对所有 SMA 亚型患者的影响，并为 SMA 的临床决策建立一个平台，有必要收集具有标准化结果标记的真实世界数据。
{"title":"An Overview of Contemporary Phenotypes, Present Challenges, and Novel Implications for Medical Services in the Diagnosis of Spinal Muscular Atrophy","authors":"Sujana A, Durga Prasad K, Divya E, Kalyani G","doi":"10.26452/fjphs.v3i4.524","DOIUrl":"https://doi.org/10.26452/fjphs.v3i4.524","url":null,"abstract":"Spinal muscular atrophy (SMA) is a form of muscle disease induced by SMN1 gene mutations. It can cause motor neurons and muscle strength to weaken. The intensity of the disease’s progression varies depending on the stage of development. Over the past ten years, new ways to help people with SMA have been found. These include the use of gene therapy and the modification of the SMN2 and SMN1 genes. First drugs approved for this condition were able to significantly alter the course of the disease. However, the evidence that is now available for these novel therapies is frequently constrained to a small range of individuals in terms of age and illness stage. To better understand the impact of treatment on people with all SMA subtypes and to build a platform for clinical decision-making in SMA, it will be necessary to gather real-world data with standardized outcome markers.","PeriodicalId":503124,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"259 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139260729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：